» Articles » PMID: 35784685

PD-L1 Regulates Platelet Activation and Thrombosis Caspase-3/GSDME Pathway

Overview
Journal Front Pharmacol
Date 2022 Jul 5
PMID 35784685
Authors
Affiliations
Soon will be listed here.
Abstract

Platelets play a central role in hemostasis and thrombosis, regulating the occurrence and development of thrombotic diseases, including ischemic stroke. Programmed death ligand 1 (PD-L1) has recently been detected in platelet, while the function of PD-L1 in platelets remain elusive. Our data reveal a novel mechanism for the role of PD-L1 on platelet activation and arterial thrombosis. PD-L1 knockout does not affect platelet morphology, count, and mean volume under homeostasis and without risk of bleeding, which inhibits platelet activation by suppressing outside-in-activation of integrin by downregulating the Caspase-3/GSDME pathway. Platelet adoptive transfer experiments demonstrate that PD-L1 knockout inhibits thrombosis. And the absence of PD-L1 improves ischemic stroke severity and increases mice survival. Immunohistochemical staining of the internal structure of the thrombus proves that PD-L1 enhances the seriousness of the thrombus by inhibiting platelet activation. This work reveals a regulatory role of PD-L1 on platelet activation and thrombosis while providing novel platelet intervention strategies to prevent thrombosis.

Citing Articles

Unlocking the therapeutic potential of tumor-derived EVs in ischemia-reperfusion: a breakthrough perspective from glioma and stroke.

Hao Z, Guan W, Wei W, Li M, Xiao Z, Sun Q J Neuroinflammation. 2025; 22(1):84.

PMID: 40089793 DOI: 10.1186/s12974-025-03405-7.


Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease.

Hayashi A, Ishihara H, Kawabe M, Kato K, Nakashima A, Yamamoto I Front Med (Lausanne). 2025; 12:1530804.

PMID: 39958825 PMC: 11826805. DOI: 10.3389/fmed.2025.1530804.


Gasdermins in sepsis.

Wang W, He Z Front Immunol. 2023; 14:1203687.

PMID: 38022612 PMC: 10655013. DOI: 10.3389/fimmu.2023.1203687.


Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.

Shafqat A, Omer M, Ahmed E, Mushtaq A, Ijaz E, Ahmed Z Front Immunol. 2023; 14:1200941.

PMID: 37520562 PMC: 10374407. DOI: 10.3389/fimmu.2023.1200941.


Role of pyroptosis in hemostasis activation in sepsis.

Zhu C, Liang Y, Luo Y, Ma X Front Immunol. 2023; 14:1114917.

PMID: 36756123 PMC: 9899792. DOI: 10.3389/fimmu.2023.1114917.

References
1.
Zhou B, Abbott D . Gasdermin E permits interleukin-1 beta release in distinct sublytic and pyroptotic phases. Cell Rep. 2021; 35(2):108998. PMC: 8106763. DOI: 10.1016/j.celrep.2021.108998. View

2.
Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores S, Brugge J . Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol. 2002; 157(2):265-75. PMC: 2199242. DOI: 10.1083/jcb.200112113. View

3.
Staessens S, Denorme F, Francois O, Desender L, Dewaele T, Vanacker P . Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance. Haematologica. 2019; 105(2):498-507. PMC: 7012484. DOI: 10.3324/haematol.2019.219881. View

4.
Brzoska T, Suzuki Y, Mogami H, Sano H, Urano T . Binding of thrombin-activated platelets to a fibrin scaffold through α(IIb)β₃ evokes phosphatidylserine exposure on their cell surface. PLoS One. 2013; 8(2):e55466. PMC: 3562181. DOI: 10.1371/journal.pone.0055466. View

5.
Blair P, Flaumenhaft R . Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009; 23(4):177-89. PMC: 2720568. DOI: 10.1016/j.blre.2009.04.001. View